Latest Conference Coverage

Cervical Dystonia Subtype, Severity Impacts OnabotulinumtoxinA Utilization

Torticollis was the most common predominant cervical dystonia presentation subtype at injection 1, followed by laterocollis.

Aducanumab’s Implications for Future Clinical Trials: Pierre N. Tariot, MD

In addition to his work study pimavanserin in treating dementia-related psychosis, the director of the Banner Alzheimer’s Institute commented on the potential for aducanumab in Alzheimer disease.

Biomarkers, Tech Advances to Improve Alzheimer Disease Prevention: Pierre N. Tariot, MD

The director of Banner Alzheimer’s Institute spoke on the importance of biomarkers in Alzheimer disease, as well as the ongoing improvements in digital technologies.

Conducting Alzheimer Disease Trials Remotely: Pierre N. Tariot, MD

Following the COVID-19 pandemic, investigators are seeing a shift towards remote trials in an effort to avoid participants having to be in-person at a brick-and-mortar site.

Addressing Neuropsychiatric Symptoms of Alzheimer Disease

Jacobo Mintzer, MD, MPA, discussed a wide range of Alzheimer disease related topics, including the use of methylphenidate, reactions to AAIC, and the aducanumab approval.

The State of Alzheimer Disease Trials: Pierre N. Tariot, MD

The director of the Banner Alzheimer’s Institute discussed areas of success and those facing challenges for Alzheimer disease clinical trials.

Innovative Alzheimer Prevention Research at IFN 2021: Richard Isaacson, MD

The director of the Alzheimer’s Prevention Clinic at Weill Cornell Medicine discussed the topics and ideas that clinicians should look forward to at the 2021 International Congress on the Future of Neurology.

Rachelle S. Doody, MD, PhD, on DIAN-TU Study Analysis, Additional Insights on Gantenerumab and Crenezumab

The global head of Neurodegeneration at Roche/Genentech offered her insights on additional analysis of the DIAN-TU trial of gantenerumab and perspectives on biomarker data.

Understanding Biomarker Trends in Alzheimer via Roche’s NeuroToolKit

The toolkit’s assays contain several biomarkers, including Aß 1-42, Aß 1-40, α-syn, GFAP, IL-6, neurogranin, NfL, phosphotau181, S100B, sTREM2, total tau, and YKL-40.

Public Misconceptions About Dementia: James E. Galvin, MD, MPH

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the real-world level of dementia education and where it needs improvement.

Improving Rural Community Dementia Knowledge, Screening Rates Using Telemedicine: James E. Galvin, MD, MPH

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed employing the MoCA-T app as a means of cognitive screening in rural and ethnically diverse populations.

Weighing Impact of Social, Lifestyle Factors on Alzheimer Disease Risk: James E. Galvin, MD

The director of the Center for Brain Health at Miami University Miller School of Medicine discussed how much influence people have on lowering their Alzheimer disease risk.

Roche’s NeuroToolKit in Alzheimer Disease Research: Rachelle S. Doody, MD, PhD

The global head of Neurodegeneration at Roche/Genentech shared insight into the development of the company’s NeuroToolKit and its use in its Alzheimer disease research.

NeuroVoices: James Galvin, MD, MPH, on Location and Greenhouse Space Effects on Alzheimer Risk

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine provided context on greenhouse spaces and their preventive benefits in Alzheimer disease.

What to Expect at the 2021 International Congress on the Future of Neurology

Program chairs Fred D. Lublin, MD, and Stephen Silberstein, MD, offer insight into the third annual IFN meeting, which is set for September 17-18, 2021, to be held in a virtual setting.

Associations Between Greenspace and Cognitive Performance: James E. Galvin, MD, MPH

The director of the Comprehensive Center for Brain Health at the University of Miami Miller School of Medicine discussed the clinical significance of his findings on neighborhood tree canopy and brain health.

Looking Forward to IFN 2021: Stephen D. Silberstein, MD

The director of the headache center at Jefferson University Hospital commented on what he is excited for at the upcoming International Congress on the Future of Neurology.

Exciting Multiple Sclerosis Debates at IFN 2021: Fred Lublin, MD

The director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center spoke on what he is looking forward to at the 2021 International Congress on the Future of Neurology.

What to Expect at IFN 2021: Jessica Ailani, MD

The director of the MedStar Georgetown Headache Center discussed the upcoming International Congress on the Future of Neurology and what attendees can expect to hear from experts in migraine.

NeuroVoices: Jacobo Mintzer, MD, MPA, on Methylphenidate’s Impact on Alzheimer Apathy

The professor of health science at the Medical University of South Carolina discussed robust results from the phase 3 ADMET 2 study evaluating methylphenidate to treat apathy in Alzheimer disease.

Approval of Aducanumab for Treatment of Alzheimer Disease: Eric Reiman, MD

The executive director of Banner Alzheimer’s Institute discussed the approval of aducanumab and the potential to address unmet needs and gaps in care for patients with Alzheimer disease.

Needs and Challenges in Alzheimer Disease Diagnosis: Eric Reiman, MD

The approval of aducanumab and other advancements in Alzheimer disease diagnosis remain at the forefront of discussion; Eric Reiman, MD, spoke on the state of diagnosis and those ongoing conversations.

Understanding P-Gingivalis’ Role in Alzheimer Disease, Periodontal Disease

Mike Detke, MD, PhD, chief medical officer, Cortexyme, provided context on atuzaginstat’s high ceiling in Alzheimer disease, its regulatory path, and its unique dental substudy.

Blood-Based Biomarkers for Alzheimer Disease: Eric Reiman, MD

The executive director of Banner Alzheimer’s Institute discussed the future of blood tests as a biomarker that may help in addressing current challenges, including drug development.

The State of the Alzheimer Disease Pipeline: Eric Reiman, MD

The executive director of Banner Alzheimer’s Institute commented on ongoing research into amyloid plaque-reducing antibody therapies, the approval of aducanumab, and other initiatives with the ability to impact the treatment of Alzheimer disease.

Greatest Challenges in Repurposing Alzheimer Drugs: Feixiong Cheng, PhD

The State of Alzheimer Disease Clinical Trials and Prevention Efforts: Eric Reiman, MD

The executive director of Banner Alzheimer’s Institute discussed the current state of AD trials, as well as his perspective on ongoing efforts to establish prevention therapies.

Identifying Impactful Biomarkers of Alzheimer Disease: Sudhir Sivakumaran, PhD; Klaus Romero, MD, MS, FCP

NeuroVoices: Mike Detke, MD, PhD, on Atuzaginstat’s Potential in Alzheimer Disease, Periodontal Disease

The chief medical officer of Cortexyme discussed the company’s investigational agent atuzaginstat, its mechanism of action, and the findings of the phase 2/3 GAIN trial.

Jeffrey Cummings, MD, ScD, on Appropriate Use Criteria for Aducanumab

Cummings and colleagues presented appropriate use criteria for the newly approved Biogen/Eisai agent at the 2021 Alzheimer’s Association International Conference.